Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor Effect on Cerebral Blood Flow and Neurocognitive Function in SCD
NCT05228821Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoint: Change in Cerebral Blood Flow at Week 24. Planned start Aug 2023; status: withdrawn.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05228821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228821.